Refractory Solid Tumors Clinical Trial
Official title:
IIT Clinical Trial on Tolerance, Safety, and Preliminary Efficacy of KSX01-TCRT Injection in Solid Tumor Subjects
1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00404508 -
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT02450136 -
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02596503 -
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT00759928 -
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06150365 -
Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
|
Early Phase 1 | |
| Completed |
NCT01247168 -
An Open-Label, Dose-Escalation Study of AZD2461
|
Phase 1 | |
| Completed |
NCT00665990 -
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
|
Phase 1 | |
| Completed |
NCT02691793 -
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
|
Phase 4 | |
| Completed |
NCT02450149 -
Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02691767 -
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
|
N/A | |
| Terminated |
NCT00664586 -
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03810742 -
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03096340 -
Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02450123 -
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
|
N/A | |
| Completed |
NCT02383368 -
A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma
|
Phase 1 | |
| Completed |
NCT00394446 -
Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03052205 -
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT02482441 -
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
|
Phase 1 | |
| Recruiting |
NCT03739827 -
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
|
||
| Recruiting |
NCT05150457 -
Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
|
Phase 1 |